Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 896-904

  Goh, Hyun Gyung ^a   Lin, Min ^b   Fukushima, Takashi ^c   Saglio, Giuseppe ^d   Kim, Dongho ^a   Choi, Soo Young ^a   Kim, Soo Hyun ^a   Lee, Jeong ^a   Lee, Young Seok ^a   Oh, Sang Mi ^a   Kim, Dong Wook ^a  

^a The Catholic University of Korea   (South Korea)

^b FLUIDIGM CORPORATION   (United States)

^c Fluidigm KK   (Japan)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

BCR ABL; Chronic myeloid leukemia; minimal residual disease; PCR negativity; polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL POLYMERASE CHAIN REACTION; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MINIMAL RESIDUAL DISEASE; NANOFLUIDICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REPLICATE REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 79955066374     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.555569     Document Type: Article

References (20)

1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384. (Pubitemid 26327486)
2. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:130-134.
3. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic myeloid leukemia with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080-7085. (Pubitemid 350276891)
4. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008;112:837-845. (Pubitemid 351240578)
5. Ross DM, Hughes T. How complete is 'complete' molecular response in imatinib-treated chronic myeloid leukemia? Leuk Lymphoma 2008;49:1230-1231. (Pubitemid 352015782)
6. Bruemmendorf TH, Cervanantes F, Kim DW, et al. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 2008;26(15 Suppl.): Abstract 7001.
7. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008;112(Suppl. 1): Abstract 186.
8. Gianantonio R, Francesca P, Fausto C, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009;114:4933-4938.
9. Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009;23:1628-1633.
10. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-397.
11. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404.
12. Branford S, Seymour JF, Grigg A, Arthur C, Lynch K, Hughes TP. Increasing frequency and marked stability of complete molecular responses is observed in imatinib-treated CML patients with long-term follow up. Blood 2006; 108(Suppl. 1): Abstract 430.
13. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28(Suppl. 1): S71-S73. (Pubitemid 38251502)
14. Hromadnikova I, Houbova B, Hridelova D, et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Prenatal Diagn 2003;23:235-238. (Pubitemid 36323685)
15. Oehler VG, Qin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia 2009;23:396-399.
16. Bhat S, Herrmann J, Armishaw P, Corbisier P, Emslie KR. Single molecule detection in nanofluidic digital array enables accurate measurement of DNA copy number. Anal Bioanal Chem 2009;394:457-467.
17. Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009;50:944-951.
18. Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
19. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:3118-3122.
20. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: significance and implications for the assessment of minimal residual disease. Blood 1998;92: 3362-3367. (Pubitemid 28492345)